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Dear Editor,
We have read with great interest the recent article by 
Tufton and coworkers reporting on the risk of metastasis in 
patients with paraganglioma (PGL) tumours associated with 
germline SDHA mutations (Tufton et al. 2017). Herein, we 
report a further case of a malignant PGL in a 46-year-old 
man with a succinate dehydrogenase complex flavoprotein 
subunit A (SDHA) germline mutation (c.91C > T, p.Arg31*). 
In the case we describe, following the initial surgical 
removal of a left-sided retroperitoneal PGL, twenty-three 
years elapsed before the development of a bony metastasis 
in the eighth left rib. This observation is similar to that 
of Tufton and coworkers who reported two patients, who 
developed metastatic disease in 16 and 37 years, respectively, 
following initial diagnosis (Tufton  et  al. 2017). During 
investigations for this case, we found that the rib metastasis 
was avid on 18-fluorodeoxyglucose (FDG) positron emission 
tomography (PET) computed tomography (CT), but not 
avid on radiolabeled I131 metaiodobenzylguanidine (MIBG) 
imaging (Fig. 1). This observation of SDHA-related malignant 
PGL is in keeping with SDHB- and SDHD-associated PGL, 
in which reduced avidity on MIBG imaging is due to 
reduced tumoural expression of noradrenaline transporters 
(Timmers et al. 2007). This clinical report supports the recent 
literature that suggests a risk of malignancy in patients 
with SDHA mutated PGL (Bausch  et  al. 2017, Casey  et  al. 
2017, Tufton  et  al. 2017). The prolonged time interval 
between diagnosis and development of metastases in our 
case suggests that SDHA-related tumours are slow growing 
but it does support long-term surveillance programmes for 
patients with germline SDHA mutations.
Although mutations in SDHB, SDHC and SDHD gene 
subunits were first identified as predisposition genes for 
the development of phaeochromocytoma (PC) and PGL 
tumours over 15 years ago, SDHA was first associated with 
PGL only seven years ago (Burnichon et al. 2010) and, more 
recently, with wild-type gastrointestinal stromal tumours 
(WT GIST) (Evenepoel  et  al. 2015). It is now recognised 
that the SDHA gene is the most common SDHx germline 
mutation implicated in development of SDH-deficient WT 
GIST (Boikos et al. 2016). Recently, the European-American-
Asian Pheochromocytoma-Paraganglioma Registry Study 
Group reported on 34 index cases with germline SDHA 
mutations and PC or PGL tumours. This group described a 
high prevalence of head and neck PGL in the SDHA cohort 
15/34 (44%) and metastatic disease was reported in 4/34 
(12%) (Bausch et al. 2017).
Here, we report the case of a 46-year-old man who first 
presented at age 23 years with headache, heat intolerance 
and abdominal pain. He was subsequently diagnosed 
with a left-sided retroperitoneal paragangliomama, which 
was surgically resected. The man had no family history 
of endocrine tumours and no additional relevant medical 
history. Following surgery, the patient was surveyed in 
primary care with annual urinary metanephrine testing. 
Twenty-three years later he was referred to our specialist 
neuroendocrine tumour service at Cambridge University 
Hospital NHS Foundation Trust, due to an elevated 
urinary normetanpehrine level (urinary normetanephrine 
5870 nmol/24 h, reference range 0–4900; urinary 
metanephrine 756 nmol/24 h, reference range 0–2000), 
which was first observed 3 months earlier. On review, the 
patient denied symptoms suggestive of catecholamine 
excess and, importantly, denied any of the symptoms that 
he reported at the time of his initial presentation. Review 
of systems revealed that his only complaint was left side rib 
pain. Previous investigations in primary care included a plain 
chest radiograph which did not reveal any abnormality.
We performed plasma metanephrine testing and found 
an elevated normetanephrine level (2864 pmol/L, reference 
range <1000 pmol/L) in the context of normal plasma 
metanephrine (197 pmol/L, reference range <600 pmol/L) 
and methoxytyramine measurements (95.6 pmol/L, 
reference range <180 pmol/L). In light of the elevated 
normetanephrine level in urine and plasma, CT of the 
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neck, thorax, abdomen and pelvis was performed and a 
metastatic deposit in the eighth left rib with no evidence 
of additional disease was identified (Fig. 1A). An 131I-MIBG 
scan was performed both for staging purposes and to 
evaluate suitability for 131I-MIBG therapy. Interestingly, the 
metastatic deposit was not avid (Fig. 1C). An 18F-FDG PET 
CT confirmed avidity (maximum standard uptake value of 
19.1) in the left rib lesion (Fig. 1B) but no additional disease 
was identified. The patient was referred for a thoracotomy 
and surgical resection of the 8th rib after appropriate pre-
operative optimisation with alpha-blockade. Subsequently, 
histological analysis confirmed the diagnosis of a metastatic 
paraganglioma with SDHB immunonegativity. SDHA 
immunohistochemistry was not performed (Fig. 1D).
Next generation sequencing of SDHA, SDHB, SDHC, 
SDHD, SDHAF2, MAX, TMEM127, VHL, RET and FH was 
performed on germline DNA from this patient after obtaining 
informed consent. The Illumina Trusight-One assay was 
used for sequencing and a mean coverage depth of >20-
fold was achieved for 98% of the regions sequenced. Whole 
exon deletions, duplications and large rearrangements are 
not detected using this method and multiple ligation probe 
analysis was performed for VHL, SDHB, SDHC and SDHD. 
This testing identified a pathogenic truncating mutation in 
the SDHA gene (c.91C > T, p.Arg31*), which was confirmed 
by Sanger sequencing.
Post-operatively, repeat plasma metanephrine levels 
returned to normal (normetanephrine, 391 pmol/L; 
metanephrine, 180 pmol/L). This patient will remain 
under regular clinical follow-up for the development of 
synchronous or metachronous tumours. Given his germline 
SDHA mutation status and previous disease avidity on 
18F-FDG PET CT, going forward, this will be the preferred 
surveillance imaging modality if there is no detectable 
disease on conventional cross-sectional imaging using CT/
MRI, in the presence of elevated plasma metanpehrine or 
methoxytyramine levels.
In summary, the case we describe provides additional 
evidence for the risk of metastatic disease in SDHA mutated 
PGL. Moreover, our report highlights the utility of 18F-FDG 
PET CT in the detection of metastatic disease in patients 
with SDHA mutations, as has previously been demonstrated 
in cases of SDHB and SDHD related tumours (Timmers et al. 
2007). Interestingly, and with relevance to optimal 
surveillance strategies for patients with germline SDHA 
mutations, the significant lag period (23  years) between 
initial presentation and the development of metastatic 
disease described in our case was also observed in two other 
cases of SDHA mutated malignant PGL (Tufton et al. 2017). 
The incidence of metastatic disease in SDHB related PC and 
PGL has been reported in two studies as 19% (Benn et al. 
2006) and 16% (Srirangalingam  et  al. 2008) over a mean 
Figure 1
(A) Demonstrates the metastatic deposit in the left 8th rib on CT as indicated by the arrow. (B) Shows the avid rib metastasis on 18F FDG PET CT and 
(C) shows no tumour avidity on I131 MIBG imaging. (D) Demonstrates loss of SDHB protein expression in the metastatic tumour deposit on SDHB 
immunostaining indicating SDH deficiency due to the detected germline mutation in SDHA (c.91C > T, p.Arg31).
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follow-up of 48 and 70  months, respectively. These data 
suggest that the development of metastatic disease may 
occur earlier in the disease course of SDHB-associated PGL/
PC. Further study is required to define the risk of malignant 
disease in SDHA-related PGL/PC and the median interval for 
the development of malignancy. Recent literature suggests 
that life-long surveillance, as recently recommended by the 
European Society of Endocrinology (Plouin et al. 2016), is 
crucial for patients with SDHA gene mutations, in addition to 
those patients with mutations in other SDH subunits (SDHB/
SDHC/SDHD). However, we acknowledge that prospective 
studies with extended follow-up periods of 15–20  years 
may be necessary to reveal the true incidence of metastasis 
in SDHx related PGL and to stratify individual surveillance 
protocols for patients based on the SDHx germline subunit 
mutation.
Ruth T Casey1,2
Benjamin G Challis2
Alison Marker3
Deborah Pitfield2
Heok K Cheow4
Ashley Shaw4
Soo-Mi Park1
Helen L Simpson5
Eamonn R Maher1
1Department of Medical Genetics, University of Cambridge 
and NIHR Cambridge Biomedical Research Centre and Cancer 
Research UK Cambridge Centre, Cambridge, UK
2Department of Endocrinology, Cambridge University NHS 
Foundation Trust, Cambridge, UK
3Department of Histopathology, Cambridge University NHS 
Foundation Trust, Cambridge, UK
4Department of Radiology, Cambridge University Hospitals 
NHS Foundation Trust, Cambridge, UK
5Department of Diabetes and Endocrinology, University 
College London Hospitals, NHS Foundation Trust, 
London, UK
(Correspondence should be addressed to R Casey; 
email: rc674@medschl.cam.ac.uk)
Declaration of interest
The authors declare that there is no conflict of interest that could be 
perceived as prejudicing the impartiality of this article.
Funding
The authors thank the following funding agencies: NIHR (E R M), European 
Research Council Advanced Researcher Award (E R M), the British Heart 
Foundation (E R M) and Health Research Board Ireland (R C).
References
Bausch B, Schiavi F, Ni Y, Welander J, Patocs A, Ngeow J, Wellner U, 
Malinoc A, Taschin E, Barbon G, et al. 2017 Clinical characterization 
of the pheochromocytoma and paraganglioma susceptibility genes 
SDHA, TMEM127, MAX, and SDHAF2 for gene-informed 
prevention. JAMA Oncology [in press]. (doi:10.1001/
jamaoncol.2017.0223)
Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, 
Croxson M, Dahia PL, Elston M, Gimm O, et al. 2006 Clinical 
presentation and penetrance of pheochromocytoma/paraganglioma 
syndromes. Journal of Clinical Endocrinology and Metabolism 91  
827–836. (doi:10.1210/jc.2005-1862)
Boikos SA, Pappo AS, Killian JK, LaQuaglia MP, Weldon FC, Georger S, 
Trent JC, von Mehren M, Wright JA, Schiffman JD, et al. 2016 
Molecular subtypes of KIT/PDGFRA Wild-type gastrointestinal 
stromal tumors: a report from the National Institutes Of Health 
Gastrointestinal Stromal Tumor Clinic. JAMA Oncology 2 922–928. 
(doi:10.1001/jamaoncol.2016.0256)
Burnichon N, Brière JJ, Libé R, Vescovo L, Rivière J, Tissier F, Jouanno E, 
Jeunemaitre X, Bénit P, Tzagoloff A, et al. 2010 SDHA is a tumor 
suppressor gene causing paraganglioma. Human Molecular Genetics 19 
3011–3020. (doi:10.1093/hmg/ddq206)
Casey RT, Ascher DB, Rattenberry E, Izatt L, Andrews KA, Simpson HL, 
Challis B, Park S-M, Bulusu VR, Lalloo F, et al. 2017 SDHA related 
tumorigenesis: a new case series and literature review for variant 
interpretation and pathogenicity. Molecular Genetics and Genomic 
Medicine 5 237–250. (doi:10.1002/mgg3.279)
Evenepoel L, Papathomas TG, Krol N, Korpershoek E, de Krijger R,  
Persu A & Dinjens WN 2015 Toward an improved definition of the 
genetic and tumor spectrum associated with SDH germ-line 
mutations. Genetics in Medicine 17 610–620. (doi:10.1038/
gim.2014.162)
Plouin PF, Amar L, Dekkers OM, Fassnacht M, Gimenez-Roqueplo AP, 
Lenders JW, Lussey-Lepoutre C, Steichen O & Guideline Working 
Group 2016 European Society of Endocrinology Clinical Practice 
Guideline for long-term follow-up of patients operated on for a 
phaeochromocytoma or a paraganglioma. European Journal of 
Endocrinology 174 G1–G10. (doi:10.1530/EJE-16-0033)
Srirangalingam U, Walker L, Khoo B, MacDonald F, Gardner D,  
Wilkin TJ, Skelly RH, George E, Spooner D, Monson JP, et al. 2008 
Clinical manifestations of familial paraganglioma and 
phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene 
mutation carriers. Clinical Endocrinology 69 587–596. 
(doi:10.1111/j.1365-2265.2008.03274.x)
Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G, 
Adams KT, Solis D, Lenders JW & Pacak K 2007 Superiority of 
fluorodeoxyglucose positron emission tomography to other 
functional imaging techniques in the evaluation of metastatic  
SDHB-associated pheochromocytoma and paraganglioma. Journal of 
Clinical Oncology 25 2262–2269. (doi:10.1200/JCO.2006.09.6297)
Tufton N, Ghelani R, Srirangalingam U, Kumar VKA, Drake W, Iacovazzo 
D, Skordilis K, Berney DM, Al-Mrayat M, Khoo B, et al. 2017 SDHA 
mutated paragangliomas may be at high risk of metastasis. Endocrine-
Related Cancer 24 L43–L49. (doi:10.1530/ERC-17-0030)
Received in final form 24 June 2017
Accepted 26 June 2017
